B2B Scientific Programme Committee: Peter Black, Canada / Caroline Moore, United Kingdom / Simon Tanguay, Canada
Learning Objectives :
At the end of this session, attendees should be able to:
Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
Recognize the role of imaging and genetic markers in guiding treatment decision-making.
Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.
.jpg "Simon Tanguay photo")